Sterling Capital Management’s Astria Therapeutics ATXS Stock Holding History

Sterling Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,383	Closed	-$31.2K	–	3213
2025 Q4	$31.2K	Sell	2,383 -150	-6%	-$1.79K	﹤0.01%	2000
2025 Q3	$18.4K	Buy	2,533 +1,379	+119%	+$9.33K	﹤0.01%	2186
2025 Q2	$6.18K	Buy	1,154 +995	+626%	+$4.82K	﹤0.01%	2402
2025 Q1	$849	Sell	159 -109	-41%	-$763	﹤0.01%	2865
2024 Q4	$2.4K	Buy	268 +208	+347%	+$2.21K	﹤0.01%	2735
2024 Q3	$661	Buy	+60	New	+$667	﹤0.01%	2744

Sterling Capital Management's ATXS Position: Q1 2026 in Review

Sterling Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 2,383 shares — an estimated $31.2K sold.

Sterling Capital Management first reported a position in ATXS in Q3 2024 and held it in 6 quarters. The position peaked at $31.2K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Sterling Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Sterling Capital Management sold 2,383 Astria Therapeutics shares in Q1 2026, an estimated $31.2K.
Sterling Capital Management first reported a position in Astria Therapeutics in Q3 2024 and held it in 6 quarters.
Sterling Capital Management's Astria Therapeutics position peaked at $31.2K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.